Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

ABC Transporters: Exporter01:31

ABC Transporters: Exporter

7.3K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
7.3K
ABC Transporters: Importer01:27

ABC Transporters: Importer

3.8K
ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

166
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
166
Active Transport01:14

Active Transport

2.8K
Active transport is a critical biological process that allows cells to move solutes against an electrochemical gradient. This process requires direct energy input and is characterized by its selectivity, saturability, and susceptibility to competitive inhibition.
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...
2.8K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

1.6K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent trajectories of psychological distress during the prolonged COVID-19 pandemic in Japan.

Scientific reports·2026
Same author

Non-necroptotic MLKL function damages mitochondria and promotes hematopoietic stem cell aging.

Nature communications·2026
Same author

AI-Enhanced Adaptive Virtual Screening Platform Enabling Exploration of 69 Billion Molecules Discovers Structurally Validated FSP1 Inhibitors.

bioRxiv : the preprint server for biology·2026
Same author

Comparison of remimazolam versus propofol under deep sedation for elderly patients during prostate biopsy: a protocol for a randomised controlled trial.

BMJ open·2026
Same author

Protein Kinase A and assembly of an ABCC4 protein network.

Nature communications·2025
Same author

Somatic mtDNA mutation burden shapes metabolic plasticity in leukemogenesis.

Science advances·2025

Related Experiment Video

Updated: Apr 18, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Leukemia and ABC transporters.

Yu Fukuda1, Shangli Lian1, John D Schuetz1

  • 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Advances in Cancer Research
|February 3, 2015
PubMed
Summary
This summary is machine-generated.

This review explores how ATP-binding cassette (ABC) transporters impact acute myeloid leukemia (AML) treatment. Blocking these transporters may enhance chemotherapy by affecting leukemic cell survival and proliferation.

Keywords:
ABC transporterAMLLeukotrienePGE(2)Porphyrin

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

949
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Related Experiment Videos

Last Updated: Apr 18, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

949
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • Acute myeloid leukemia (AML) has a poor prognosis, with limited response to current chemotherapy.
  • ATP-binding cassette (ABC) transporters are implicated in chemotherapy resistance, but their role may be more complex.
  • These transporters export endogenous substrates crucial for normal hematopoietic progenitor function.

Purpose of the Study:

  • To review the multifaceted role of ABC transporters in AML.
  • To explore how endogenous substrates exported by ABC transporters influence leukemic progenitor cells.
  • To suggest novel therapeutic strategies involving ABC transporter inhibitors.

Main Methods:

  • Literature review of studies on ABC transporters, endogenous substrates, and AML.
  • Analysis of the impact of endogenous substrate export on hematopoietic and leukemic progenitor cells.
  • Discussion of potential therapeutic implications of targeting ABC transporters.

Main Results:

  • ABC transporters export endogenous ligands that can support leukemic progenitor proliferation and survival.
  • This export mechanism offers a potential advantage to leukemic cells.
  • Targeting ABC transporters could overcome chemotherapy resistance.

Conclusions:

  • The role of ABC transporters in AML is not limited to drug efflux but also involves the export of critical endogenous molecules.
  • Inhibiting ABC transporters alongside chemotherapy may improve treatment efficacy.
  • Further research into ABC transporter substrates and inhibitors is warranted for AML therapy.